The Egyptian Drug Authority (EDA) has announced the release of a new section of the Egyptian Drug Formulary dedicated to Blood disorder medications. This section includes a wealth of information targeted at healthcare professionals, focusing on key drugs registered in the Egyptian market for the treatment of blood disorders, particularly anemia medications, anticoagulants, blood thinners, and treatments for hemophilia.

This release aims to provide pharmacists and other healthcare professionals with accurate and up-to-date information on drug usage and the rational use of pharmaceutical treatments. The goal is to ensure that patients receive better healthcare, enjoy an improved quality of life, and benefit from the optimal use of resources, thereby reducing overall medical costs.

The Egyptian Drug Registry covers key points, including:

The pharmacological classification of medications.

Indications for use.

Dosages, their adjustments, and methods of administration or preparation.

Major drug interactions.

Contraindications, precautions, warnings, and side effects.

This initiative reflects the Egyptian Drug Authority’s commitment to improving pharmaceutical services for patients, ensuring the highest levels of pharmaceutical care, patient safety, and the optimal use of medications. It is based on global references to elevate the profession of pharmacy.